Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mycenax BiotechROCO:4726 -4.67%43 Days Payable is 19.07 as of Dec. 2025, which is 27% below its 10-year median of 26.01. GuruFocus rates ROCO:4726 with a GF Score™ of 43/100 and a GF Value™ of NT$47.88 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Mycenax Biotech ranks worse than 89.3% on this metric.
The historical rank and industry rank for Mycenax Biotech's Days Payable or its related term are showing as below:
ROCO:4726'
s Days Payable Range Over the Past 10 Years
Min: 15.52 Med: 26.01 Max: 47.49
Current: 19.45
During the past 13 years, Mycenax Biotech's highest Days Payable was 47.49. The lowest was 15.52. And the median was 26.01.
ROCO:4726's Days Payable is ranked worse than 89.3% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:4726: 19.45
Mycenax Biotech's Days Payable
increased
from Dec. 2024 (17.96) to Dec. 2025 (19.07).
It may suggest that Mycenax Biotechdelayed paying its suppliers.
Mycenax Biotech Days Payable Related Terms
Mycenax Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Mycenax Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4726 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Mycenax Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mycenax Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Mycenax Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mycenax Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mycenax Biotech (ROCO:4726) has a Days Payable of 19.07 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mycenax Biotech and its competitors. This is 27% below median its historical median of 26.01. Over the past decade, Mycenax Biotech's Days Payable has ranged from 15.52 to 47.49. According to the industry distribution chart, Mycenax Biotech ranks #626 out of 701 companies in the Biotechnology industry, placing it in the top 89.3%.
Is Mycenax Biotech's Days Payable too high?
Mycenax Biotech's current Days Payable of 19.07 is 27% below median its 10-year median of 26.01. Over the past 10 years, this metric has ranged from a low of 15.52 to a high of 47.49. The Biotechnology industry median Days Payable is 112.84. Mycenax Biotech's value of 19.07 is 83.1% below this industry median. Based on the distribution chart, Mycenax Biotech ranks #626 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mycenax Biotech has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mycenax Biotech ranks #626 out of 701 companies for Days Payable. This places Mycenax Biotech in the lower half of its industry. The industry median Days Payable is 112.84. Mycenax Biotech's value of 19.07 is 83.1% below this benchmark. Historically, Mycenax Biotech's own Days Payable has ranged from 15.52 to 47.49 over the past decade. While the company's 10-year median is 26.01 vs. the industry median of 112.84, Mycenax Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mycenax Biotech's current Days Payable of 19.07 is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mycenax Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mycenax Biotech's current Days Payable is 19.07, which is 27% below median its own 10-year median of 26.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$24.50 — trading 48.8% below its estimated fair value. The current Days Payable is 19.07, which is 27% below median its 10-year median of 26.01 and 83.1% below the Biotechnology industry median of 112.84. Mycenax Biotech's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Days Payable is 19.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?
Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued.
The current stock price of NT$24.50 is trading 48.8% below its estimated GF Value™ of NT$47.88.
GuruFocus considers Mycenax Biotech to be Possible Value Trap.
Key valuation signals for ROCO:4726:
Days Payable: 19.07 (27% below median its 10-year median of 26.01)
GF Value™: NT$47.88 vs. price of NT$24.50 (48.8% below fair value)
Industry Position: 83.1% below the Biotechnology median (#626 of 701)
No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
43GF Score
Get the complete analysis for ROCO:4726
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4726 has been successfully added to your 
